Through this analysis, they suggested that BPC-157 might activate focal adhesion kinase (FAK) and paxillin, two proteins that play a significant role in cellular processes
For the latter two, the decision to attempt retreatment depends on the extent of the reaction and if there are therapeutic alternatives
This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 5 for better accuracy
BPC-157 has a favorable safety profile across 100+ published studies, primarily in animal models
Occasional reports include temporary fatigue or lethargy (5-10% of users), mild headaches in the first few days of use, slight water retention, or transient flushing at injection sites
The cumulative incidence of cutaneous infection was 1.1% at 1 year of therapy, 6.4% at 5 years, and 17.6% at 10 years